Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABR and pembrolizumab before surgery in early-stage NSCLC
NL-OMON49358Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- May 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Vrije University Medical Center. Primary endpoint: Immune modulation in tumor and lymphoid compartments. Started May 2018; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON49358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49358.